Compare Tenet Healthcare Corporation (THC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tenet Healthcare Corporation vs TransMedics Group Inc — how do they compare? Tenet Healthcare Corporation trades at $196.03 (market cap $16.74B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Tenet Healthcare Corporation is far larger — about 6.6× TransMedics Group Inc's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| THC | TMDX | |
|---|---|---|
Market Cap | $16.74B | $2.54B |
Sector | Health | Technology |
52-Week High | $244.80 | $150.42 |
52-Week Low | $148.38 | $61.99 |
Enterprise Value | $26.99B | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tenet Healthcare (THC) trades at $194.38, down 0.27% on the day, with a neutral technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $4.82 exceeding expectations of $4.17. Valuation metrics appear attractive with a P/E of 10.14 and P/S of 0.79, while profitability remains robust with 82.47% gross margins and 37.87% ROE. Recent news highlights the company's expanding outpatient footprint through USPI as a key growth driver.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and a $235.88 price target representing 21% upside potential. The company's solid earnings momentum and defensive healthcare positioning during market volatility provide stability. Key risks include execution challenges in outpatient expansion and potential regulatory headwinds affecting hospital operations. Cash flow trends show improvement with projected net cash flow narrowing from -$136M in 2025 to -$32M in 2026.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
